CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

May 29-31, 2020; Online at meetings.asco.org/am
Biomarker evaluation suggests that prolonged PFS with nivo plus ipi may be associated with enhanced expression of genes involved in the tumor microenvironment and inflammatory responses; PD-L1 expression is not predictive for OS or PFS.
Format: Microsoft PowerPoint (.ppt)
File Size: 278 KB
Released: June 3, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

Downloadable slideset with key highlight data from the virtual 2021 ASCO GU Cancers Symposium provided by Clinical Care Options (CCO)

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 25, 2021

CCO Conference Coverage of ASCO GU 2021 with downloadable slides and experts’ commentaries of clinically relevant studies

Robert Motzer, MD Daniel P. Petrylak, MD Released: February 4, 2021

In this slideset from Clinical Care Options, Brian Costello, MD, MS discusses data on selecting therapy for patients with advanced RCC

Brian A. Costello, MD, MS Released: January 22, 2021

Brian Costello, MD, discusses personalizing care and improving outcomes for patients with advanced RCC, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: January 22, 2021 Expired: January 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue